Insulin

Incretin Mimetic Drugs Overtake Insulin in Total Prescriptions and Costs for Commercially Insured Patients

Retrieved on: 
Wednesday, January 10, 2024
General Health, Professional Services, Pharmaceutical, Data Management, Payments, Technology, Health Technology, Health Insurance, Data Analytics, Insurance, Health, Diabetes, Patient, Dulaglutide, C-peptide, Kidney failure, Doctor of Pharmacy, Stroke, Heart failure, Prescription, Business development, Risk, Insulin, Pharmacy, CPR, Product management, Benchmarking, Pharmaceutical industry

An analysis by Cedar Gate Technologies found that incretin mimetic prescription medications (also known as GLP-1 agonists) have overtaken insulin in total prescriptions and cost among commercially insured patients.

Key Points: 
  • An analysis by Cedar Gate Technologies found that incretin mimetic prescription medications (also known as GLP-1 agonists) have overtaken insulin in total prescriptions and cost among commercially insured patients.
  • The data unveils a significant 36.1% increase in GLP-1 agonist prescriptions and a 43.4% surge in costs for these medications.
  • In contrast, insulin prescriptions experienced a 1.4% decrease during the same period, transitioning from the top-prescribed diabetes drug class in the preceding year to the second position on the list.
  • They accounted for $544 million and $487 million, respectively, in total costs in a single year for pharmacy claims included in Cedar Gate’s analysis.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Continuity, Diabetes, Entrepreneurship, Risk, C3, Non-alcoholic fatty liver disease, Epilepsy, FDA, CR2, Anticonvulsant, Inflammation, Neuron, Geographic atrophy, Conference, Paratriathlon, Pain, European, Disease, Cmax, Glycated hemoglobin, Trigeminal neuralgia, FGF21, Steatosis, Therapy, Computational biology, Exophthalmos, TED, Diplopia, Varenicline, Smoking, Injection, AAV, CNS, DSM-IV codes, Patient, Graves' ophthalmopathy, Medicine, Seizure, Glucokinase, Neurology, CR1, NASH, Insulin, Brain, GMP, Trigeminal nerve, Ophthalmology, Pathology, Fibrosis, Pharmaceutical industry

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today provided an update on its pipeline of gene therapies for prevalent conditions including geographic atrophy, thyroid eye disease, diabetes, NASH, trigeminal neuralgia and epilepsy. Kriya is advancing the first of its gene therapy product candidates into the clinic in 2024 and expects up to five programs in the clinic by the end of 2025.

Key Points: 
  • Kriya’s pipeline includes gene therapies across three major therapeutic areas: ophthalmology, metabolic disease and neurology.
  • Its programs share the following features: direct-to-tissue delivery, validated biology, de-risked clinical and regulatory paths and large commercial markets.
  • Dr. Ramaswamy will share further information on Kriya’s portfolio during his presentation at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th at 9:00 AM PT in San Francisco, California.
  • A significant proportion of patients suffer from refractory epilepsy, many of whom are candidates for invasive neurosurgery.

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

Retrieved on: 
Monday, January 8, 2024
Phase, Disease, Health, Diabetes, Insulin, Trial of the century, MD, Clinical trial, DSM-IV codes, Person, Cancer, Patient, Diagnosis, Safety, Hypoglycemia, Pharmaceutical industry

The clinical study, COVALENT-112, has initiated enrollment of adults living with type 1 diabetes in the US and Canada.

Key Points: 
  • The clinical study, COVALENT-112, has initiated enrollment of adults living with type 1 diabetes in the US and Canada.
  • Eligible patients include those who have been diagnosed with type 1 diabetes for up to 15 years.
  • Beta cell loss is thought to be a root cause of type 1 and type 2 diabetes.
  • Preclinical studies have shown the potential of BMF-219 to specifically proliferate insulin-producing beta cells in animal models of type 1 and type 2 diabetes.

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook

Retrieved on: 
Monday, January 8, 2024
Software, Mobile, Wireless, General Health, Hardware, Consumer Electronics, Medical Devices, Technology, Health Technology, Wearables, Mobile Technology, FDA, Health, Diabetes, Stelo, Eastern Time Zone, CGM, International, Diet, Insulin, DXCM, Dexcom, Sleep, Growth, Acceleration, Exercise, Pharmaceutical industry

DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022.

Key Points: 
  • DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022.
  • U.S. revenue is expected to be approximately $765 million, representing growth of 26% over the fourth quarter of 2022. International revenue is expected to be approximately $265 million, an increase of 27% over the fourth quarter of 2022.
  • For fiscal 2023, total preliminary, unaudited revenue is expected to be approximately $3.62 billion, an increase of 24% over 2022.
  • “Through our expanding product portfolio, Dexcom is defining the future of sensing technology and empowering people to take control of health.”
    Dexcom will report its audited full fourth quarter and fiscal 2023 financial results on Thursday, February 8, 2024 after the close of market.

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Kidney, Metabolic acidosis, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Lithium, UGT, Risk, Digoxin, Shanda, Hypotension, FDA, SGLT1, Type 2 diabetes, Acute kidney injury, Congress, Pyelonephritis, Conference, Fever, Ketoacidosis, Pregabalin, Pregnancy, Pain, Assessment, Gabapentin, Tenderness, New Drug Application, Amber Grid, HCM, Common, SGLT2, PROGRESS, Hypertrophic cardiomyopathy, Diabetes, Kidney, Heart failure, Dialysis, History, Patient, Prescription, Type, Neuropathic pain, Webcast, Insulin, T2DM, EGFR, Erythema, T1DM, Hypoglycemia, Partnership, Contraindication, Diarrhea, NDA, Incidence, Swelling, Urinary tract infection, Hospital, Chronic kidney disease, Internationalized domain name, Metabolic acidosis, Creatinine, Growth, Lactation, Pharmaceutical industry

THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.

Key Points: 
  • THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.
  • “Lexicon achieved major advancements in 2023 in its business and pipeline of pharmaceutical innovations,” said Lonnel Coats, chief executive officer and director of Lexicon.
  • The company will also focus on ensuring a strong ongoing awareness of INPEFA in the medical community through medical publications and congress presence.
  • Company to Present at J.P. Morgan Healthcare Conference Thursday, January 11, 2024 at 10:30am PST (1:30pm ET)
    Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation.